Efficacy and safety of Buyang Huanwu Decoction for early-stage diabetic nephropathy: a Meta-analysis.
10.19540/j.cnki.cjcmm.20190109.001
- Author:
Jie ZHAO
1
;
Chao MO
2
;
Li-Feng MENG
2
;
Chun-Qin LIANG
1
;
Xiang CAO
1
;
Wei SHI
2
Author Information
1. Guangxi University of Chinese Medicine Nanning 530001,China.
2. Nephrology Department of First Affiliated Hospital,Guangxi University of Chinese Medicine Nanning 530023,China.
- Publication Type:Journal Article
- Keywords:
Buyang Huanwu Decoction;
Meta-analysis;
early-stage diabetic nephropathy;
system evaluation
- MeSH:
Diabetic Nephropathies;
drug therapy;
Drugs, Chinese Herbal;
therapeutic use;
Humans;
Randomized Controlled Trials as Topic
- From:
China Journal of Chinese Materia Medica
2019;44(8):1660-1667
- CountryChina
- Language:Chinese
-
Abstract:
Buyang Huanwu Decoction(BHD) has the effect in benefiting Qi and activating blood circulation,and is the representative prescription for benefiting Qi and activating blood. At present,it is used for treatment of early diabetic nephropathy. However,its efficacy and safety remained to be verified. Therefore,this study aims to systematically evaluate the efficacy and safety of Buyang Huanwu Decoction for early-stage diabetic nephropathy. Data of randomized controlled trials(RCTs) of Buyang Huanwu Decoction for earlystage diabetic nephropathy were collected through the retrieval of electronic databases,including PubMed,EMbase,the Cochrane Library,CBM,CNKI,VIP and Wan Fang Data from inception to September 16,2018. Two reviewers independently screened out literatures,extracted data,and assessed the risk of bias. And then Meta-analysis was conducted by Rev Man 5. 3 software. A total of 15 RCTs involving 1 402 patients were included. The results of Meta-analysis indicated that Buyang Huanwu Decoction and conventional treatment group(combination treatment group) were superior to conventional treatment group in reducing 24 h urinary albumin excretion rates(MD =-40. 23,95% CI[-71. 25,-9. 21],P = 0. 01) and total cholesterol(MD =-0. 75,95% CI[-1. 02,-0. 48],P <0. 000 01). The effects of the two groups in reducing serum creatinine were similar(MD =-1. 48,95%CI[-4. 48,1. 53],P = 0. 34).However,the reduction of triglyceride was affected by the course of treatment. The effects were similar in less than or equal to eight weeks(MD =-0. 33,95%CI[-0. 97,0. 31],P = 0. 31),whereas the combination group was superior to the conventional treatment group in 12 weeks(MD =-0. 30,95%CI[-0. 58,-0. 22],P = 0. 03) and more than or equal to 16 weeks(MD =-0. 49,95% CI[-0. 9,-0. 08],P= 0. 02). There were no significant difference in adverse events between the two groups(OR= 1. 38,95%CI[0. 28,6. 8],P = 0. 69). The results showed that combination treatment group has a significantly higher efficacy on early diabetic nephropathy.The above conclusion shall be verified with more high-quality RCTs because of the low quality of the included studies.
